Khiron Life Sciences closes sale of its European business

On November 17, 2023, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron") announced that it had completed the sale of its European subsidiaries, being Khiron Europe GmbH, Zerenia Clinics Limited, PharmaDrug Production GmbH, Khiron Life Sciences UK Limited and Khiron Life Sciences Spain SL to 2518542 Alberta Ltd., a company controlled by Avonlea-Drewry Holdings Inc., for an aggregate base purchase price of $3,000,000.

Khiron is a leading global medical cannabis company with core operations in Latin America. Leveraging wholly owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide.

Gowling WLG advised Khiron with respect to this sale with a team that included Peter Simeon, Josh Almario, Ashley Andaya, James Stewart and Jevaughn Johnson.